House committee unanimously approves health plan transparency package

By Allison Bell – The House Energy & Commerce Committee has created a large package — an updated version of the Lower Costs, More Transparency Act of 2026 bill — to serve as a vehicle for many different health-related disclosure proposals and proposals for cutting prescription drug costs. Members of the committee voted 45-0 to approve the 248-page package at a meeting held Tuesday. The package was created as an "amendment in the nature of a substitute," or AINS, to an earlier version of the Lower Costs bill that focused on health care cost disclosures. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Broad Transparency and Disclosure Requirements: The updated Lower Costs package combines multiple health transparency proposals into a single legislative vehicle. It would require health plans, insurers and service providers to disclose more detailed information about contracts, administrative costs and medical spending. Hospitals would face expanded and strengthened price transparency rules. Collectively, these measures aim to give employers, consumers and policymakers greater visibility into how health care dollars are spent.

2. New Reporting Standards for Prior Authorization and Plan Operations: The legislation would mandate annual public reporting on prior authorization practices, including which services require approval and denial rates. Service providers to employer-sponsored plans would have to share contract and compensation details at least twice a year. Insurers would also need to break down how premium revenue is allocated between medical claims and overhead. These provisions could increase accountability for plan administrators and insurers.

3. Uncertain Legislative Path Forward: Although the committee approved the package unanimously, its route to enactment remains fluid. Lawmakers had considered attaching health reforms to a budget reconciliation measure that could pass the Senate with a simple majority, but the current reconciliation vehicle does not include the package. House leaders could still fold it into a revised reconciliation bill or attempt to move it as standalone legislation. The outcome will determine how quickly, and in what form, the new requirements might take effect.

Insurers Are Rejecting More Prescriptions Than Ever, New Study Finds

By Wendell Potter – A new study published in JAMA puts hard numbers behind something patients and doctors have been telling me for years: getting a prescription filled increasingly means running an obstacle course of denials, prior authorization forms, and step therapy requirements — and a lot of people never make it through. Read Full Article...

HVBA Article Summary

1. Sharp Increase in First-Time Prescription Rejections: The analysis of more than 2 million first-time attempts to fill brand-name prescriptions without generic alternatives found that denial rates climbed significantly over the study period. By 2024, insurers were rejecting 40.7% of initial fill attempts, up from 24.3% in 2018, representing a 67% rise. Overall, nearly one-third of first-time prescription attempts were denied. The findings suggest patients are encountering more administrative barriers at the pharmacy counter than in prior years.

2. Many Patients Receive No Alternative Treatment After Denial: Among patients whose prescriptions were rejected, 48.4% received no medication in the same drug class within 90 days. Only 38.6% ultimately obtained the originally prescribed drug, while 13% received a different drug in the same class. Even when coverage was eventually approved, patients experienced an average delay of 12.2 days. These gaps indicate that denials can translate into delayed or foregone treatment for a substantial share of patients.

3. Rejection Rates Vary Widely by Insurance Type: The study found notable differences across coverage categories. Plans in the ACA marketplace and Medicaid managed care had rejection rates near or above 48%, meaning nearly half of prescriptions were initially denied. In contrast, traditional Medicare drug plans and Medicare Advantage plans had considerably lower rejection rates, at 24.0% and 19.8%, respectively. These disparities suggest that a patient’s insurance source plays a significant role in whether a prescribed medication is approved.

Trump threatens tariffs on imported generic drugs

By Kristin Jensen – President Trump turned his attention to generic drugmakers on Tuesday night, threatening them with 200% tariffs within three years if they don’t move production to the U.S. In a Truth Social post, Trump said he would impose 100% tariffs on generic drugs brought into the U.S. starting on Aug. 1, 2028 and 200% thereafter. “This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time,” Trump said. Trump offered no details on the policy’s legal justification, how it would be implemented or whether it would affect only finished drugs or the importation of ingredients that generic drugmakers use to manufacture the products that go to consumers. Read Full Article...

HVBA Article Summary

1. Generic Drugmakers Face Unique Financial Strain: Unlike brand-name pharmaceutical companies, generic manufacturers typically operate on thinner profit margins. Analysts and policy experts warn that steep import levies could disproportionately affect these companies, potentially leading to discontinued products or supply shortages. A Brookings report cited in the article suggests that aggressive cost-cutting to offset tariffs might also raise concerns about manufacturing quality. As a result, the generic sector could experience more disruption than its branded counterparts.

2. Legal and Policy Uncertainty Clouds Proposal: The administration has not clarified how the tariffs would be structured or justified under existing trade law. The article notes a prior Supreme Court ruling that limited the president’s ability to impose tariffs unilaterally, adding uncertainty to the proposal’s viability. It is also unclear whether the tariffs would apply only to finished medicines or extend to imported active ingredients. These unanswered questions leave companies and investors unsure about the potential scope and timing of any changes.

3. Market Reaction Highlights Company-Specific Risk: Investor responses varied depending on each company’s exposure to imported finished drugs versus domestic production. Companies seen as more reliant on overseas manufacturing experienced sharper stock declines in early trading. Analysts indicated that firms insulated from tariffs on finished products, particularly those with more U.S.-based operations, could fare better under the proposal. The immediate share price movements reflect broader concerns about how tariff details could reshape competitive dynamics in the generic drug market.

Health insurance traps a quarter of U.S. workers in unwanted jobs

By Josephine Walker – Almost a quarter of workers in the U.S. — 23 million adults — are experiencing " job lock," staying in roles they don't want to avoid losing health insurance benefits, according to a new Gallup analysis. Read Full Article...

HVBA Article Summary

1. Financial strain strongly correlates with job lock: Workers who view health care as a major financial burden are significantly more likely to remain in roles they would otherwise leave. Among those facing high stress from medical costs, more than half report staying put to keep their coverage. The pattern is also pronounced among individuals with medical debt or who borrowed money for care, indicating that out-of-pocket pressures reinforce employment decisions. These findings suggest that affordability challenges are directly shaping labor market mobility.

2. Chronic conditions increase dependence on employer coverage: Employees with one or more chronic illnesses report higher rates of job lock than those without ongoing health issues. The likelihood rises further for people managing multiple diagnoses, particularly conditions requiring continuous or intensive treatment. Because these workers rely more heavily on stable insurance benefits, they may perceive greater risk in changing jobs. This dynamic underscores how health status can influence career flexibility.

3. Women experience disproportionate impact: The survey indicates that women report job lock at higher rates than men and are more likely to face financial strain from medical expenses. A larger share of women live with chronic conditions, compounding the pressure to maintain employer-sponsored insurance. These overlapping factors help explain gender gaps in career mobility tied to health coverage. The data points to structural health cost burdens that may affect workplace advancement and satisfaction.

Cigna expands AI-powered care management programs for members

By Paige Minemyer – Cigna Healthcare is taking steps to significantly expand its personalized care management programs, leaning on AI to identify risks sooner and simplify the patient journey. Read Full Article...

HVBA Article Summary

1. AI-Driven Early Intervention Strategy: Cigna is expanding its use of predictive analytics to flag members who may be at risk of developing or worsening complex conditions. By identifying these individuals earlier, the insurer aims to intervene before complications escalate. The program supports conditions such as cancer, heart disease, kidney disease, high-risk pregnancy and behavioral health disorders. Executives say earlier detection can produce both clinical improvements and financial benefits.

2. Demonstrated Clinical and Financial Impact: Cigna projects that the expanded care management programs will reduce medical costs for engaged members by an average of $2,000 per year, totaling an estimated $200 million in savings over three years. The company also reports a 42% drop in avoidable inpatient stays among participants. Screening and identification timelines have improved as well, accelerating potential diagnoses for breast, colon and lung cancers by several weeks. Additionally, 72% of members with depression who connected to behavioral health specialists experienced meaningful clinical improvement.

3. Human-Centered Model Supported by Technology: While artificial intelligence underpins the program enhancements, Cigna emphasizes that clinicians remain central to care delivery. More than 1,250 clinicians—including nurse managers and behavioral health professionals—help coordinate services and connect members to available benefits. The insurer reports a 95% satisfaction rate among surveyed participants, suggesting strong member engagement. Leadership argues that accessible, person-to-person communication—by phone, text or digital channels—remains critical even as technology advances.

How primary care can implement patient-centered AI policy

By Sara Heath – As AI adoption continues to grow throughout the healthcare sector, primary care specialties will need to plan for patients who are both excited and fearful of how the technology affects their care. Read Full Article...

HVBA Article Summary

1. Patients Hold Mixed but Nuanced Views on AI in Primary Care: Interviews conducted for the Commonwealth Fund report show that patients simultaneously recognize AI’s promise and fear its unintended consequences. Many see AI as inevitable and potentially helpful in improving care coordination and understanding of medical information. At the same time, they worry about how technology is introduced and whether their perspectives are considered. This duality means providers must approach AI adoption with sensitivity to both optimism and skepticism.

2. Concerns Center on Trust, Equity and Clinical Oversight: Patients expressed apprehension about issues such as inaccurate outputs, cognitive deskilling among clinicians and the risk of widening existing health disparities. They are particularly concerned that people with limited internet access, older devices or lower digital health literacy could be left behind. Respondents also want reassurance that AI will not replace their physician’s judgment. These concerns underscore the importance of maintaining strong human oversight and equitable access as AI tools are deployed.

3. Patient-Centered Implementation Requires Transparency and Accountability: The report recommends clear disclosure and consent processes, including explanations through patient portals and in-person materials. Patients want multiple opportunities to understand how AI is used and to opt out in certain situations, such as ambient scribing. Providers are encouraged to train clinicians in responsible AI use and to measure patient-focused outcomes, including satisfaction with technology. Conducting health equity audits and ensuring compatibility with low-bandwidth or older devices are also key steps toward more inclusive AI adoption.

Why aren’t health insurers rushing to cover GLP-1 prescriptions for beneficial weight loss?

By Dave Pearson – In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them. Read Full Article...

HVBA Article Summary

1. Long-Term Savings Depend on Sustained Use: Although GLP-1 drugs have demonstrated strong clinical effectiveness and broad popularity, real-world adherence presents a challenge. Studies indicate that many patients discontinue the medications, often regaining weight and diminishing potential long-term health benefits. This pattern weakens the projected downstream savings from avoided procedures and chronic disease management. For insurers, inconsistent use complicates the financial case for broad coverage.

2. High Upfront Costs Strain Budgets: Independent evaluations, including research published in the Journal of Managed Care & Specialty Pharmacy and an ICER report, conclude that GLP-1 therapies can provide significant societal value. However, their current prices—driven by demand, patent protections and complex manufacturing—create substantial short-term budget impacts for payers. Even if the treatments are cost-effective over time, the immediate financial exposure across large eligible populations is considerable. Insurers must weigh this budget pressure against potential long-term gains.

3. Coverage Is Targeted and Scrutinized: Insurers are more likely to reimburse GLP-1 drugs for specific diagnoses such as diabetes, sleep apnea or extremely high BMI, rather than for general weight loss. Coverage for broader or less-defined indications may become more restrictive as payers manage utilization. At the same time, regulators have warned about unapproved compounded versions of GLP-1 drugs entering the market, raising safety and quality concerns. These dynamics add complexity to payer decision-making around access and affordability.